Glioblastoma multiforme

Ultima Vez Modificado: 14 de septiembre del 2008

Share article


Imprima English

Question

Dear OncoLink "Ask The Experts,"

My grandfather was diagnosed with Glioblastoma multiforme last August. He had as much of the tumor removed as possible. I am researching possible treatments to prolong his life. He’s been on radiation and chemotherapy. His oncologists have stopped chemotherapy and all other treatments. I’m confident that they haven’t considered MAb425 treatment. Is this something to be considered?

Answer

Robert Lustig MD FACR, Clinical Associate Professor, Department of Radiation Oncology, University of Pennsylvania, responds:

If the chemotherapy was stopped due to progression of tumor, then further investigational treatment can be delivered. There are at least 20-30 different agents being tested. Based on published data to date, the combination of Avastin (a vascular endothelial growth factor inhibitor, or VEGF inhibitor) and Irinotecan (a chemotherapy drug) has the best results. If the chemotherapy was stopped due to completion of planned therapy, then he should be scanned every 2 months as surveillance, and treated again if/ when the tumor returns.

Imprima English
News
AANS: Vaccine Improves Survival in Glioblastoma Multiforme

Apr 18, 2012 - Use of autologous heat shock protein-peptide vaccine is associated with improved survival for patients with recurrent glioblastoma multiforme, according to a phase II study presented at the annual meeting of the American Association of Neurological Surgeons, held from April 14 to 18 in Miami.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información